Abstract

Purpose: To develop a model to select appropriate candidates for irradiation stent placement among patients with unresectable pancreatic cancer with malignant biliary obstruction (UPC-MBO).Methods: This retrospective study included 106 patients treated with an irradiation stent for UPC-MBO. These patients were randomly divided into a training group (74 patients) and a validation group (32 patients). A clinical model for predicting restenosis-free survival (RFS) was developed with clinical predictors selected by univariate and multivariate analyses. After integrating the radiomics signature, a combined model was constructed to predict RFS. The predictive performance was evaluated with the concordance index (C-index) in both the training and validation groups. The median risk score of progression in the training group was used to divide patients into high- and low-risk subgroups.Results: Radiomics features were integrated with clinical predictors to develop a combined model. The predictive performance was better in the combined model (C-index, 0.791 and 0.779 in the training and validation groups, respectively) than in the clinical model (C-index, 0.673 and 0.667 in the training and validation groups, respectively). According to the median risk score of 1.264, the RFS was significantly different between the high- and low-risk groups (p < 0.001 for the training group, and p = 0.016 for the validation group).Conclusions: The radiomics-based model had good performance for RFS prediction in patients with UPC-MBO who received an irradiation stent. Patients with slow progression should consider undergoing irradiation stent placement for a longer RFS.

Highlights

  • MATERIALS AND METHODSPancreatic cancer is one of the leading causes of cancer-related death [1], and it has the lowest five-year relative survival rate among those with any type of cancer [2]

  • The subgroup analysis of overall survival according to tumor etiology showed better survival for biliary tract cancer, there did not appear to be a significant difference in patients with pancreatic cancer [12]

  • We proposed a novel model incorporating clinical biomarkers and computed tomography (CT) radiomics features to predict restenosis-free survival (RFS) for individual patients with UPCMBO who undergoing irradiation biliary stent placement

Read more

Summary

Introduction

MATERIALS AND METHODSPancreatic cancer is one of the leading causes of cancer-related death [1], and it has the lowest five-year relative survival rate among those with any type of cancer (approximately 8% for all stages) [2]. Less than 20% of patients with pancreatic cancer are candidates for surgical resection [3, 4], and over half of them develop obstructive jaundice [5]. Considering that patients with advanced pancreatic cancer have only a 6– 10 month median survival, the general treatment is palliative care [6]. Placement of a self-expanding metal stent is the standard palliative care for UPC patients with malignant biliary obstruction (MBO) [8,9,10]. It is important to select appropriate candidates with pancreatic cancer to undergo irradiation stent placement, for individual and reasonable stent selection, and for prolonged patency and improved survival

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call